despit
advanc
nutrit
genet
hous
therapeut
diseas
respiratori
reproduct
gastrointestin
tract
domest
anim
poultri
continu
major
caus
morbid
mortal
although
vaccin
develop
licens
prevent
mani
diseas
need
improv
vaccin
efficaci
new
vaccin
reason
low
vaccin
efficaci
includ
inappropri
unstabl
outdat
antigen
vaccin
prepar
eg
vitro
express
antigen
instead
vivo
express
antigen
inappropri
immun
respons
eg
system
instead
mucos
type
instead
type
vise
versa
inappropri
use
otherwis
efficaci
vaccin
eg
inappropri
time
vaccin
tizard
overview
vaccin
current
licens
vaccin
domest
anim
wildlif
mucos
rout
provid
tabl
mani
vaccin
consist
pathogen
attenu
tradit
method
engin
virusvector
vaccin
use
extens
mucos
parenter
rout
veterinari
medicin
major
current
poultri
vaccin
attenu
agent
deliv
ovo
oral
intranas
mucos
rout
reason
eas
administr
economi
protect
efficaci
comparison
fewer
vaccin
domest
mammal
deliv
mucos
rout
manag
practic
mammal
differ
poultri
mass
vaccin
techniqu
mucos
deliveri
develop
poultri
pursu
zealous
mammal
recent
howev
number
attenu
live
vaccin
administr
develop
respiratori
tract
infect
use
tradit
methodolog
improv
protect
efficaci
rapid
onset
immun
compar
kill
vaccin
product
led
widespread
accept
attenu
live
oral
vaccin
enter
diseas
also
market
mani
case
efficaci
disappoint
due
lack
potenc
adult
interfer
matern
antibodi
suckl
anim
better
strategi
induct
immun
gastrointestin
tract
need
especi
neonat
presenc
matern
antibodi
contrast
effect
parenter
vaccin
common
diseas
reproduct
tract
veterinari
speci
avail
year
littl
motiv
develop
mucos
vaccin
mani
diseas
respiratori
gastrointestin
tract
devast
neonat
period
diseas
activ
immun
may
provid
protect
natur
exposur
pathogen
matern
vaccin
enhanc
passiv
immun
wide
use
veterinari
medicin
especi
control
enter
diseas
practic
difficulti
aris
howev
diseas
parvoviru
enter
puppi
smooth
transit
must
made
protect
passiv
matern
antibodi
protect
activ
immun
without
permit
window
diseas
suscept
transit
difficult
achiev
induct
activ
immun
commonli
inhibit
matern
antibodi
variou
strategi
use
address
problem
improv
vaccin
adjuv
antigen
deliveri
system
would
improv
reliabl
neonat
immun
although
progress
made
diseas
prevent
veterinari
speci
ever
chang
manag
practic
eg
earlier
wean
piglet
larger
anim
oper
gener
new
pattern
diseas
requir
new
control
strategi
emerg
new
pathogen
eg
porcin
reproduct
respiratori
syndrom
viru
prrsv
porcin
provid
new
challeng
vaccin
research
older
challeng
met
chapter
focu
mucos
veterinari
vaccin
vaccin
concept
relat
select
pathogen
econom
import
intent
highlight
progress
review
exist
futur
vaccin
strategi
acknowledg
uniqu
contribut
research
understand
mucos
vaccin
immunolog
respiratori
tract
infect
major
caus
morbid
mortal
farm
anim
poultri
pet
diseas
condit
intensifi
current
manag
practic
mix
recent
wean
stress
beef
calv
multipl
sourc
auction
barn
certain
diseas
condit
atroph
rhiniti
pig
result
interplay
sever
pathogen
multipl
agent
must
repres
vaccin
respiratori
pathogen
mycoplasma
hyopneumonia
young
pig
caus
new
pattern
diseas
manag
practic
chang
eg
wean
earlier
age
requir
chang
vaccin
strategi
pathogen
prrsv
recent
emerg
improv
vaccin
await
advanc
understand
agent
diseas
pathogenesi
discuss
respiratori
vaccin
even
major
pathogen
veterinari
speci
beyond
scope
present
review
section
focu
vaccin
prrsv
infect
pig
influenza
hors
illustr
gener
principl
porcin
reproduct
respiratori
syndrom
prr
chronic
reproduct
respiratori
diseas
pig
caus
prrsv
member
famili
arterivirida
benfield
et
al
sign
associ
prr
anorexia
fever
lethargi
pneumonia
redblu
discolor
ear
vulva
delay
return
sow
estru
wean
abort
fetal
mummif
stillborn
weak
born
piglet
high
prewean
mortal
mengel
et
al
prrsv
preval
swineproduc
countri
worldwid
annual
econom
loss
pork
industri
unit
state
due
prr
estim
million
holtkamp
kliebenstein
accord
american
anim
plant
health
inspect
servic
aphi
report
januari
unvaccin
pig
unit
state
seroposit
prrsv
infect
pig
excret
prrsv
saliva
nasal
secret
urin
milk
colostrum
fece
low
level
intermitt
also
semen
infect
boar
rossow
et
al
absenc
control
measur
prrsv
spread
aerosol
fomit
personnel
prrsv
divid
two
distinct
genotyp
type
european
type
ii
north
american
genotyp
contain
subtyp
strain
genet
divers
vari
virul
pathogen
kim
et
al
immun
one
genotyp
prrsv
may
provid
partial
protect
reinfect
reflect
complex
prrsv
genet
immunolog
variat
among
strain
botner
et
al
swine
known
speci
suscept
prrsv
alveolar
macrophag
primari
permiss
cell
prrsv
present
pulmonari
intravascular
space
lymph
node
thymu
heart
spleen
placenta
umbil
cord
may
also
infect
viru
halbur
et
al
effici
rapid
host
respons
virus
consist
product
type
interferon
ifn
prrsvinfect
pig
innat
secret
significantli
suppress
albina
et
al
viru
dampen
innat
nk
cellmedi
cytotox
earli
day
postinfect
renukaradhya
et
al
dwivedi
et
al
pig
signific
correl
observ
prrsv
infect
increas
express
associ
reduc
express
et
al
induct
mediat
interact
prrsv
protein
cell
dc
prrsv
nucleocapsid
protein
induc
product
peripher
blood
mononuclear
cell
pbmc
alveolar
wongyanin
et
al
delay
onset
protect
cellmedi
immun
cmi
prrsv
dwivedi
et
al
dysregul
immun
respons
infect
pig
affect
viral
pathogenesi
diseas
sever
suscept
secondari
microbi
infect
thanawongnuwech
et
al
renukaradhya
et
al
immun
respons
prrsv
inadequ
complet
clear
viru
viremia
disappear
week
viru
persist
tonsil
lymphoid
tissu
sever
month
moyronquiroz
et
al
prrsv
infect
germfre
convent
rais
pig
associ
polyclon
b
cell
activ
hypergammaglobulinemia
lymphoid
adenopathi
renal
lesion
lymphoid
hyperplasia
cooper
et
al
polyclon
lymphoplasia
also
occur
mice
infect
lactat
dehydrogenaseelev
viru
relat
viru
grossmann
et
al
primari
antibodi
respons
occur
promptli
prrsv
infect
loemba
et
al
major
secret
antibodi
autoantibodi
prrsv
nonneutr
antibodi
lemk
et
al
virusneutr
antibodi
na
respons
weak
delay
mateu
et
al
kill
modifi
live
viru
mlv
prrsv
vaccin
avail
commerci
intramuscular
intraderm
administr
charerntantanakul
mlv
vaccin
confer
protect
genet
homolog
prrsv
incomplet
protect
heterolog
virus
mengel
et
al
prrsvinfect
mlvprrsvvaccin
pig
virusspecif
cellmedi
immun
respons
either
delay
dampen
revers
virul
major
concern
modifi
live
vaccin
numer
report
revers
prrsv
vaccin
viru
virul
presenc
revert
vaccin
strain
prrsv
unvaccin
sow
pig
vaccinederiv
viru
isol
fetus
stillborn
dead
piglet
indic
spread
diseas
vaccin
pig
identif
mutat
multipl
vaccinederiv
isol
ident
posit
viral
genom
suggest
strong
select
pressur
critic
viral
protein
field
situat
avail
kill
prrsv
vaccin
fail
protect
even
homolog
viru
elicit
na
induc
weak
cellmedi
immun
respons
bassaganyariera
et
al
pregnant
sow
gilt
breed
boar
protect
prrsv
due
lack
safe
protect
vaccin
control
prrsv
breed
stock
critic
prevent
vertic
horizont
transmiss
viru
earli
attempt
develop
kill
prrsv
vaccin
use
recombin
prrsv
protein
plasmid
express
viral
gene
inactiv
prrsv
administ
without
adjuv
unsuccess
charerntantanakul
howev
recent
studi
show
promis
kill
prrsv
vaccin
coadminist
cpg
oligodeoxynucleotid
adjuv
ligand
induc
antibodi
virusspecif
cell
secret
zhang
et
al
anoth
studi
prrsv
inactiv
uv
light
binari
ethylenimin
induc
na
protect
pig
homolog
viral
challeng
suppress
effect
live
prrsv
product
lost
viru
inactiv
uv
irradi
vanhe
et
al
oral
immun
strategi
use
prrsv
nucleocapsid
protein
genet
fuse
cholera
toxin
ct
stimul
prrsv
antibodi
respons
intestin
detect
respons
vagin
secret
hyland
et
al
lack
success
develop
protect
kill
prrsv
vaccin
may
reflect
inabl
present
kill
prrsv
antigen
effect
pig
immun
system
like
live
prrsv
kill
viru
may
induc
immunosuppress
effect
addit
antigen
mass
use
kill
vaccin
may
insuffici
suggest
need
potent
adjuv
novel
deliveri
system
attempt
made
improv
mlvprrsv
vaccin
use
adjuv
one
studi
pig
inject
recombin
porcin
ct
within
week
intramuscular
administr
mlvprrsv
ct
enhanc
antibodi
respons
respect
foss
et
al
howev
use
adjuv
reduc
sever
viremia
unfortun
prrsv
na
respons
assay
protect
heterolog
challeng
assess
studi
prrsv
gain
entri
respiratori
reproduct
mucos
surfac
caus
diseas
primarili
mucos
site
therefor
mucos
vaccin
prrsv
may
effect
strategi
control
diseas
recent
attempt
elicit
protect
mucos
immun
prrsv
unsuccess
probabl
due
lack
appropri
adjuv
prrsv
infect
rapidli
subvert
host
immun
respons
effect
adjuv
must
overcom
immunosuppress
caus
vaccin
viru
simultan
potenti
virusspecif
adapt
immun
panel
bacteri
prepar
deriv
mycobacterium
vibrio
streptococcu
speci
potent
adjuv
rodent
model
test
mlvprrsv
bonavida
et
al
barral
brenner
base
mucos
system
immun
respons
three
prepar
mycobacterium
tuberculosi
whole
cell
lysat
tb
wcl
ct
b
subunit
product
streptococcu
pyogen
select
viral
challeng
trial
tb
wcl
significantli
dampen
prrsv
immunosuppress
effect
enhanc
virusspecif
adapt
respons
renukaradhya
et
al
dwivedi
et
al
histor
heatkil
mycobacteria
recogn
potent
adjuv
effect
compon
freund
complet
adjuv
fca
use
extens
experiment
anim
use
fca
human
food
anim
unaccept
due
sever
granulomat
inflammatori
reaction
toxic
cell
wall
compon
bekierkunst
howev
nontox
watersolubl
purifi
fraction
tb
wcl
werner
et
al
adjuv
properti
rodent
guinea
pig
rabbit
pig
inocul
tb
wcl
detect
sign
toxic
local
system
dwivedi
et
al
b
recombin
vaccin
prrsv
express
bacillu
calmetteguerin
bcg
report
reduc
clinic
sign
prr
decreas
viremia
viral
load
tissu
basto
et
al
crossprotect
immun
prrsv
evalu
pig
receiv
mlvprrsv
tb
wcl
challeng
virul
heterolog
prrsv
viru
kim
et
al
reduc
clinic
diseas
viremia
virusmedi
immunosuppress
note
addit
secret
lung
blood
lymphocyt
respons
prrsv
nucleocapsid
protein
enhanc
dwivedi
et
al
guillonneau
et
al
report
similar
find
mice
vaccin
adjuv
influenza
vaccin
enhanc
virusspecif
cytotox
cell
memori
respons
intern
viral
protein
note
well
crossprotect
immun
studi
passiv
protect
pig
prrsv
na
indic
modest
na
titer
protect
pregnant
sow
reproduct
failur
block
placent
transmiss
infect
prevent
viremia
piglet
provid
steril
immun
osorio
et
al
pig
immun
mlvprrsv
alon
tb
wcl
develop
na
titer
respect
postimmun
dwivedi
et
al
pig
immun
mlvprrsv
tb
wcl
challeng
prrsv
na
titer
persist
pid
dwivedi
et
al
rel
low
number
circul
virusspecif
secret
cell
report
pig
vaccin
mlvprrsv
without
adjuv
cell
per
million
pbmc
dwivedi
et
al
contrast
meier
et
al
report
secret
cell
per
million
pbmc
pig
vaccin
aujeszki
diseas
viru
pig
immun
mlvprrsv
tb
wcl
challeng
prrsv
greater
secret
cell
per
million
pbmc
twofold
higher
frequenc
cell
dwivedi
et
al
literatur
concern
mucos
immun
respons
pig
respiratori
tract
limit
compar
studi
rodent
human
recent
research
highlight
advantag
activ
mucos
immun
system
use
vaccin
deliv
potent
adjuv
induct
adequ
immun
respons
respiratori
reproduct
tract
essenti
control
prr
swine
indeliv
potent
mucos
vaccin
gener
better
crossprotect
immun
genet
variabl
prrsv
field
virus
effort
control
prr
outbreak
use
convent
parenter
deliv
vaccin
limit
success
develop
altern
approach
gener
immun
respiratori
tract
prioriti
particular
mucos
adjuv
base
compon
mycobacteri
speci
show
promis
respiratori
tract
diseas
affect
virtual
everi
aspect
equin
husbandri
includ
work
pleasur
race
hors
consider
effort
expend
prevent
epizoot
respiratori
diseas
stabl
fair
show
race
track
equin
influenza
viru
discuss
detail
exampl
past
current
futur
vaccin
approach
equin
influenza
viru
caus
epizoot
upper
lower
respiratori
tract
diseas
almost
worldwid
equin
influenza
exclud
contin
australia
import
restrict
quarantin
august
year
import
infect
hors
led
explos
epizoot
equin
influenza
estim
hors
infect
period
callinan
demonstr
potenti
viru
spread
unvaccin
popul
infect
occur
hors
age
epizoot
often
involv
younger
anim
van
maanen
cullinan
clinic
sign
includ
high
fever
persist
dri
cough
nasal
discharg
anorexia
depress
secondari
bacteri
pneumonia
may
complic
clinic
pictur
equin
influenza
virus
classifi
type
influenza
antigen
differ
hemagglutinin
h
neuraminidas
n
glycoprotein
defin
two
recogn
subtyp
wilson
two
lineag
american
european
identifi
multipl
viru
strain
includ
vaccin
sinc
protect
heterolog
strain
incomplet
yate
mumford
antigen
drift
suffici
requir
regular
reapprais
strain
includ
vaccin
mumford
wood
natur
infect
induc
iga
antibodi
nasal
secret
igga
iggb
antibodi
serum
nelson
et
al
circul
cytotox
lymphocyt
protect
reinfect
persist
least
year
hannant
et
al
vaccin
inactiv
viru
vaccin
induc
serum
igg
antibodi
without
detect
iga
nasal
secret
nelson
et
al
without
cytotox
cell
activ
van
maanen
cullinan
two
three
dose
vaccin
typic
administ
primari
seri
booster
dose
least
year
thereaft
frequent
vaccin
advis
hors
high
risk
infect
wilson
protect
typic
incomplet
limit
durat
improv
adjuv
enhanc
level
durat
antibodi
respons
inactiv
viru
vaccin
mumford
et
al
suppress
effect
matern
antibodi
respons
inactiv
vaccin
led
recommend
vaccin
foal
month
age
van
oirschot
et
al
subunit
equin
influenza
vaccin
base
immun
stimul
complex
iscom
adjuv
technolog
licens
market
europ
sinc
newmark
antibodi
respons
iscombas
vaccin
typic
higher
titer
persist
convent
inactiv
vaccin
mumford
et
al
protect
demonstr
experiment
challeng
month
three
dose
vaccin
seri
mumford
et
al
protect
may
due
part
abil
iscomadjuv
vaccin
induc
cytotox
lymphocyt
morein
et
al
although
iscombas
vaccin
induc
iga
antibodi
respons
follow
administr
hu
et
al
commerci
influenza
iscom
vaccin
administ
parenter
administr
inactiv
equin
influenza
viru
ct
b
report
induc
local
iga
antibodi
protect
experiment
challeng
hannant
et
al
coldadapt
temperaturesensit
live
vaccin
administr
avail
commerci
protect
experiment
challeng
demonstr
month
singl
vaccin
notabl
improv
efficaci
practic
convent
kill
vaccin
experiment
plasmid
vaccin
encod
hemagglutinin
gene
equin
influenza
examin
hors
three
dose
plasmid
administ
skin
mucos
site
tongu
conjunctiva
third
eyelid
induc
protect
clinic
diseas
partial
protect
viral
shed
protect
clinic
diseas
reduc
plasmid
administ
skin
lunn
et
al
canarypoxvector
equin
influenza
vaccin
express
hemagglutinin
two
strain
equin
influenza
avail
commerci
intramuscular
administr
sinc
toulemond
et
al
australian
epizoot
vaccin
use
extens
govern
program
erad
equin
influenza
vector
vaccin
chosen
program
diva
distinguish
infect
vaccin
anim
characterist
kirkland
delbridg
infect
hors
mount
antibodi
respons
viral
nucleoprotein
addit
viral
hemagglutinin
wherea
vaccin
hors
respond
hemagglutinin
express
vaccin
vector
recent
report
indic
adequ
antibodi
respons
gener
littl
day
primari
secondari
vaccin
elhag
et
al
protect
experiment
challeng
also
note
week
singl
dose
vaccin
poni
toulemond
et
al
respiratori
pathogen
eg
hyopneumonia
pig
critic
antigen
associ
protect
immun
respons
identifi
pathogen
eg
prrsv
also
need
identifi
appropri
type
immun
respons
need
protect
complex
diseas
condit
eg
bovin
respiratori
diseas
complex
continu
uncertainti
whether
relev
contribut
pathogen
identifi
although
mani
parenter
vaccin
efficaci
reduc
lower
respiratori
tract
diseas
need
investig
whether
induct
mucos
immun
upper
airway
combin
system
immun
reduc
infect
rate
transmiss
pathogen
econom
loss
final
need
devis
implement
chang
manag
procedur
reduc
diseas
exposur
nonimmunolog
method
optim
immun
intervent
improv
time
vaccin
vaccin
prevent
reproduct
tract
diseas
receiv
much
emphasi
veterinari
medicin
especi
true
foodproduc
anim
reproduct
failur
major
econom
problem
although
vaccin
prevent
reproduct
interest
abandon
pet
deer
area
overpopul
section
deal
vaccin
design
prevent
infecti
diseas
reproduct
mucosa
infect
caus
advers
pregnanc
outcom
classifi
rout
infect
hematogen
ascend
sever
hematogen
infect
predilect
gravid
uteru
result
earli
late
abort
includ
leptospirosi
chlamydi
infect
brucellosi
sever
anim
speci
histophilu
somni
infect
cattl
sheep
neospora
caninum
cattl
although
vaccin
avail
sever
infect
vaccin
brucellosi
avail
sinc
well
known
sever
brucella
speci
caus
abort
epididymitisorch
primari
host
brucella
abortu
cattl
brucella
sui
swine
brucella
melitensi
goat
brucella
ovi
sheep
brucella
cani
dog
brucella
marinum
brucella
delphini
marin
mammal
infect
may
acquir
via
gut
mucosa
conjunctivaupp
respiratori
mucosa
local
reticuloendotheli
system
endometriumplacenta
system
spread
thu
system
vaccin
effect
modifi
live
b
abortu
vaccin
along
test
slaughter
erad
program
success
control
bovin
brucellosi
north
america
modifi
live
vaccin
b
abortu
strain
effect
stimul
cmi
critic
protect
facult
intracellular
pathogen
strain
larg
replac
new
attenu
strain
stimul
antibodi
respons
known
interfer
diagnost
serolog
assay
consider
inform
mechan
system
immun
brucellosi
neospora
caninum
also
caus
abort
hematogen
rout
vaccin
avail
weston
et
al
histophilu
somni
infect
either
hematogen
rout
ascend
genit
rout
caus
abort
infertil
vaccin
avail
sinc
focu
volum
mucos
immun
said
concern
protect
hematogen
infect
genit
tract
ascend
local
infect
reproduct
tract
usual
transmit
sexual
two
best
exampl
vaccin
sexual
transmit
infect
anim
campylobact
fetu
subsp
venereali
formerli
vibrio
fetu
subsp
venereali
tritrichomona
foetu
hostspecif
bovin
sexual
transmit
diseas
std
infect
reproduct
mucosa
extracellular
pathogen
invad
mucosa
reproduct
tract
may
found
placenta
fetu
local
natur
infect
transmiss
limit
coitu
suggest
mucos
immun
must
import
vaccin
avail
c
fetu
subsp
venereali
sever
decad
use
control
diseas
develop
countri
vaccin
discuss
first
vibriosi
campylobacteriosi
chronic
bacteri
genit
infect
overt
clinic
sign
reproduct
failur
corbeil
et
al
month
infect
uteru
clear
first
follow
vagina
convalesc
immun
partial
protect
limit
time
antibodi
effect
protect
extracellular
pathogen
demonstr
system
passiv
immun
berg
et
al
antibodi
respons
infect
primarili
iga
vagina
igg
uteru
corbeil
et
al
system
immun
whole
cell
vaccin
result
antibodi
respons
surfac
antigen
serum
uterin
vagin
secret
corbeil
et
al
respons
prevent
infect
rapidli
clear
infect
cow
corbeil
winter
vaccin
use
prophylact
even
therapeut
immun
efficaci
even
though
surfac
antigen
variat
occur
face
local
immun
respons
corbeil
winter
presum
immun
clearanc
occur
dynam
interact
protect
evas
shift
favor
host
appear
occur
earlier
respons
primarili
igg
iga
predomin
corbeil
et
al
may
relat
abil
igg
antibodi
mediat
opson
intracellular
kill
bacterium
abil
iga
antibodi
lack
corbeil
winter
although
work
done
mani
year
ago
set
preced
system
immun
prophylaxi
therapi
reproduct
mucos
infect
trichomoniasi
similar
chronic
genit
mucos
infect
cattl
caus
protozoan
foetu
result
pregnanc
loss
trichomona
vaginali
caus
human
std
also
associ
advers
pregnanc
outcom
thu
bovin
trichomoniasi
serv
model
immun
prevent
bovin
human
reproduct
mucos
infect
econom
signific
bovin
trichomoniasi
chemotherapi
approv
investig
focus
immunoprophylaxi
immunotherapi
foetu
colon
vagin
uterin
preputi
surfac
month
like
c
fetu
subsp
venereali
infect
fact
matur
bull
often
infect
life
wherea
young
bull
may
clear
infect
time
cobo
et
al
probabl
relat
innat
immun
trichomonad
anaerob
parasit
found
deep
uterin
gland
epitheli
crypt
peni
prepuc
rhyan
et
al
oxygen
tension
probabl
lowest
older
bull
deeper
epitheli
crypt
may
lower
oxygen
tension
order
understand
protect
acquir
immun
respons
monoclon
antibodi
mab
put
protect
function
chosen
immunoaffin
purif
highli
glycosyl
surfac
antigen
bondur
et
al
corbeil
et
al
analysi
mani
isol
foetu
indic
two
mab
recogn
differ
epitop
antigen
conserv
isol
test
glycosyl
surfac
antigen
later
shown
lipophosphoglycan
lpg
protein
complex
system
immun
immunoaffinitypurifi
lpgcontain
surfac
antigen
follow
intravagin
challeng
foetu
result
significantli
earlier
clearanc
parasit
vaccin
anim
control
bondur
et
al
corbeil
et
al
importantli
clearanc
immun
anim
often
occur
week
infect
parsonson
et
al
show
signific
inflamm
accompani
reproduct
failur
occur
week
infect
vaccin
protect
fetal
loss
analysi
vaccineinduc
antibodi
respons
demonstr
predominantli
respons
serum
iga
plu
antibodi
secret
corbeil
et
al
ige
antibodi
also
increas
infect
ige
antibodi
increas
mast
cell
degranul
clearanc
foetu
occur
studi
rais
sever
question
first
system
respons
lpgprotein
complex
skew
toward
respons
cattl
respons
question
investig
second
igg
iga
antibodi
lpgcontain
antigen
protect
ig
isotyp
enrich
enhanc
protect
address
latter
question
preliminari
studi
done
mice
determin
best
rout
adjuv
enrich
igg
iga
genit
secret
subcutan
prime
immunoaffinitypurifi
lpgcontain
surfac
antigen
call
antigen
quil
adjuv
subcutan
boost
whole
cell
enrich
igg
antibodi
genit
secret
wherea
subcutan
prime
intravagin
boost
greatli
enrich
iga
antibodi
genit
secret
cattl
immun
two
method
challeng
intravagin
foetu
predominantli
iga
predominantli
antibodi
genit
secret
equal
protect
later
studi
similar
immun
show
stimul
common
mucos
immun
system
gave
result
similar
intravagin
immun
rais
question
induct
site
local
immun
respons
genit
tract
other
suggest
genit
tract
induct
site
cell
mucosaassoci
lymphoid
tissu
malt
present
true
cattl
well
mice
peopl
howev
even
though
control
cow
histolog
demonstr
malt
uteru
vagina
cow
experiment
infect
foetu
similar
lymphoid
nodul
follicl
modifi
epithelium
detect
preputi
penial
surfac
bull
infect
foetu
rhyan
et
al
immunostain
parallel
section
mab
antigen
indic
uptak
antigen
epitheli
cell
larg
dc
basement
membran
near
lymphoid
follicl
rhyan
et
al
similar
antigen
uptak
detect
infect
femal
uterin
vagin
mucosa
corbeil
et
al
thu
even
though
parasit
noninvas
releas
antigen
appear
taken
epitheli
cell
rat
uterin
epitheli
cell
present
antigen
helper
cell
wira
rossol
also
dc
posit
antigen
antigenpres
cell
apc
detect
iga
antibodi
genit
secret
infect
bull
cobo
et
al
rhyan
et
al
cow
histolog
demonstr
follicl
put
apc
suggest
induct
site
genit
tract
form
respons
antigen
stimul
like
c
fetu
subsp
venereali
foetu
mechan
evas
immun
respons
includ
coat
surfac
ig
nonspecif
epitop
variat
ikeda
et
al
cleavag
complement
compon
extracellular
cystein
proteinas
talbot
et
al
kania
et
al
studi
cystein
proteinas
inhibitor
demonstr
decreas
cytotox
foetu
bovin
trophoblast
cell
decreas
infect
mous
model
confirm
like
role
cystein
proteinas
pathogenesi
cobo
et
al
even
mechan
immun
evas
c
fetu
clear
dynam
interact
host
parasit
made
favor
host
system
local
immun
use
whole
cell
vaccin
prevent
foetu
infect
reproduct
failur
cow
demonstr
clinic
trial
kvasnicka
et
al
firstgener
whole
cell
vaccin
commerci
avail
prevent
trichomoniasi
cow
earlier
clark
et
al
demonstr
efficaci
immun
bull
whole
foetu
cell
crude
membran
glycoprotein
probabl
contain
antigen
studi
indic
vaccin
bull
could
prevent
infect
clear
alreadi
establish
infect
vaccin
bovin
trichomoniasi
immunoprophylact
immunotherapeut
recent
studi
show
vaccin
bull
commerci
avail
whole
cell
kill
foetu
vaccin
oil
adjuv
result
protect
challeng
high
level
igg
antibodi
serum
preputi
secret
cobo
et
al
antibodi
whole
cell
foetu
antigen
predomin
fairli
high
level
antibodi
also
detect
studi
c
fetu
subsp
venereali
foetu
show
std
prevent
even
cure
system
vaccin
male
femal
least
one
std
igg
iga
antigen
specif
equal
protect
mucos
surfac
either
system
immun
mucos
intravagin
immun
system
boost
protect
induct
site
form
mucosa
infect
male
femal
genit
tract
even
noninvas
pathogen
strong
appropri
immun
respons
clear
microbi
infect
genit
tract
even
microb
multipl
immun
evas
mechan
fact
protect
two
std
demonstr
natur
outbr
host
cattl
advantag
murin
model
std
vaccin
latter
human
pathogen
usual
inocul
unnatur
murin
host
diseas
mimic
human
infect
furthermor
although
inbr
mice
provid
homogen
experiment
anim
repres
variat
immun
respons
seen
outbr
human
popul
work
bovin
vibriosi
trichomoniasi
demonstr
protect
field
condit
two
std
caus
advers
pregnanc
outcom
outbr
host
encourag
preced
control
human
std
relat
advers
pregnanc
outcom
futur
need
includ
identif
protect
antigen
std
antibodymedi
protect
genit
mucosa
sever
question
yet
address
far
know
role
ige
genit
tract
larg
unstudi
even
though
seem
involv
clearanc
trichomonad
bovin
genit
tract
lastli
manipul
genit
immun
respons
enhanc
type
respons
unexplor
research
area
enter
diseas
major
caus
mortal
morbid
anim
agent
caus
diarrhea
anim
includ
virus
eg
adenovirus
pestivirus
calicivirus
coronavirus
parvovirus
rotavirus
torovirus
bacteria
eg
campylobact
spp
clostridium
spp
diarrheagen
escherichia
coli
salmonella
spp
yersinia
spp
parasit
eg
coccidia
spp
cryptosporidium
parvum
infect
occur
commonli
suckl
anim
poultri
week
age
may
also
common
postwean
suscept
seroneg
stress
adult
anim
saif
jackwood
induct
local
secretori
iga
siga
antibodi
prevent
attach
invas
neutral
toxin
infecti
agent
mucos
cellular
immun
respons
intracellular
bacteria
virus
vaccin
essenti
protect
enter
pathogen
peyer
patch
pp
mesenter
lymph
node
two
import
organ
gutassoci
lymphoid
tissu
galt
domest
anim
serv
induct
site
gut
immun
respons
ileal
pp
domest
anim
sheep
cattl
pig
dog
differ
jejun
pp
serv
primari
lymphoid
organ
similar
bursa
fabriciu
chicken
unlik
human
rodent
pp
secondari
lymphoid
organ
chu
liu
yasuda
et
al
cryptopatch
cluster
lymphoid
cell
basal
lamina
propria
occur
mice
absent
pig
pabst
et
al
mucos
lymphoid
tissu
lymphoid
cell
domest
anim
human
differ
tolllik
receptor
tlr
express
function
bind
ligand
compar
mice
iwasaki
medzhitov
tohno
et
al
guzylackpiri
et
al
differ
immun
compon
suggest
vaccin
studi
carri
mice
may
fail
translat
domest
anim
human
enter
pathogen
differ
characterist
relat
intestin
tropism
replic
requir
differ
vaccin
strategi
enter
virus
predilect
replic
distinct
vertic
longitudin
region
small
larg
intestin
cytolyt
infect
enterocyt
lead
vari
degre
villou
loss
fusion
reduc
small
intestin
absorpt
capac
malabsorpt
maldigest
diarrhea
saif
secretori
diarrhea
also
induc
virus
rotaviru
rv
involv
viral
enterotoxin
nonstructur
protein
andor
stimul
enter
nervou
system
ball
et
al
lundgren
et
al
thu
viral
diarrhea
variabl
sever
act
via
multipl
mechan
differ
enter
bacteria
caus
secretori
diarrhea
mediat
enterotoxin
fairbroth
gyle
enteropathogen
virus
divid
three
type
type
ii
iii
accord
prefer
site
replic
intestin
review
saif
type
transmiss
gastroenter
viru
tgev
rv
ii
viru
infect
prevent
induc
local
intestin
immun
wherea
type
iii
virus
parvoviru
infect
crypt
enterocyt
basolater
prevent
induc
system
immun
enteropathogen
bacteria
determin
virul
factor
includ
adhes
factor
fimbria
pili
enterotoxin
therefor
bacteri
vaccin
gener
need
prevent
attach
toxin
action
within
intestin
fairbroth
gyle
follow
section
review
vaccin
strategi
differ
type
enter
infect
tgev
rv
vaccin
pig
review
illustr
find
use
domest
outbr
anim
instead
inbr
laboratori
rodent
model
neonat
protect
enter
infect
provid
passiv
lactogen
immun
achiev
immun
mother
preparturit
pioneer
work
done
bohl
saif
earli
live
oral
virul
tgev
pig
foundat
gutmammari
glandsiga
immunolog
axi
later
becam
basi
concept
common
mucos
immun
system
studi
show
tgev
seroneg
sow
oral
immun
virul
tgev
induc
high
rate
protect
suckl
neonat
associ
high
titer
siga
antibodi
colostrum
milk
wherea
system
immun
induc
mainli
igg
antibodi
saif
et
al
rotaviru
major
caus
dehydr
diarrhea
young
livestock
infant
poultri
saif
fernandez
multipl
rv
serogroup
base
common
inner
capsid
antigen
ah
multipl
g
glycoprotein
p
proteasesensit
serotyp
base
neutral
epitop
genotyp
base
sequenc
analysi
group
rv
detect
human
sheep
swine
cattl
hors
dog
cat
poultri
wildlif
est
kapikian
martella
et
al
among
distinct
rv
serogroup
gp
serotypesgenotyp
crossprotect
limit
antigen
diverg
among
differ
serogenotyp
rv
present
challeng
design
vaccin
capabl
induc
heterotyp
protect
commerci
modifi
live
kill
rv
vaccin
rv
diarrhea
livestock
poultri
limit
group
rv
saif
fernandez
mebu
et
al
develop
first
oral
rv
vaccin
calv
year
prior
discoveri
human
rv
use
cell
cultureadapt
neonat
calf
diarrhea
rv
strain
although
signific
reduct
morbid
mortal
observ
field
trial
among
vaccin
calv
major
herd
compar
previou
year
subsequ
field
studi
reveal
variabl
efficaci
experiment
studi
suggest
matern
antibodi
interf
live
oral
vaccin
replic
suppress
develop
activ
immun
saif
fernandez
neonat
gnotobiot
pig
model
use
investig
immun
respons
rv
vaccin
infect
nearli
three
decad
saif
et
al
yuan
saif
gonzalez
et
al
gnotobiot
pig
free
matern
antibodi
placent
transfer
ig
occur
swine
immunocompet
birth
maintain
asept
free
exposur
extran
wildtyp
rv
assur
exposur
singl
pathogen
analyz
initi
studi
conduct
mimic
natur
rv
infect
bohl
et
al
studi
immun
correl
protect
gonzalez
et
al
yuan
et
al
understand
sequenc
kinet
immun
respons
stimul
virul
rv
allow
determin
marker
protect
immun
pathogen
use
design
vaccin
stimul
protect
immun
without
induc
patholog
gnotobiot
pig
oral
inocul
virul
porcin
human
rv
complet
protect
homotyp
heterotyp
distinct
gp
type
rv
challeng
hoshino
et
al
saif
et
al
signific
correl
observ
protect
rvinduc
diarrhea
shed
follow
immun
paramet
number
intestin
iga
rv
antibodysecret
cell
asc
serum
intestin
iga
rv
antibodi
titer
frequenc
intestin
rvspecif
produc
cell
yuan
et
al
et
al
yuan
saif
yuan
et
al
immun
paramet
significantli
higher
virul
rv
inocul
pig
inocul
attenu
inactiv
rv
ward
et
al
pig
inocul
two
three
dose
attenu
rv
moder
protect
diarrhea
dose
dose
viru
shed
dose
dose
homotyp
challeng
suggest
need
multipl
dose
suitabl
mucos
adjuv
enhanc
efficaci
rv
vaccin
yuan
et
al
yuan
et
al
yuan
saif
gnotobiot
pig
inocul
virul
rv
develop
acut
proinflammatori
serum
cytokin
profil
coincid
peak
diarrhea
viremia
follow
immedi
increas
cytokin
convalesc
cytokin
respons
gnotobiot
pig
inocul
one
dose
attenu
rv
show
lower
earli
proinflammatori
cytokin
respons
compar
virul
rv
inocul
pig
attenu
virul
rv
inocul
pig
develop
cytokinesecret
cell
csc
respons
week
postinocul
howev
attenu
rv
inocul
pig
develop
lower
intestin
higher
intestin
splenic
csc
compar
virul
hrv
inocul
pig
azevedo
et
al
virul
rv
inocul
pig
significantli
higher
protect
rate
rv
challeng
diarrhea
shed
respect
compar
one
dose
attenu
rv
inocul
pig
diarrhea
shed
respect
azevedo
et
al
find
suggest
higher
protect
rate
associ
earli
proinflammatori
cytokin
respons
promot
cytotox
cell
activ
viral
clearanc
later
induc
cytokin
import
protect
siga
antibodi
respons
thu
protect
rv
pig
requir
balanc
respons
azevedo
et
al
gonzalez
et
al
infect
gnotobiot
pig
virul
rv
caus
earli
recruit
innat
apc
dc
cell
ileum
enhanc
express
among
apc
spleen
zhang
et
al
wen
et
al
wen
et
al
virul
rvinfect
pig
plasmacytoid
dc
major
produc
serum
along
innat
immun
cell
cell
apc
cytokin
import
control
earli
rv
viral
replic
subsequ
develop
protect
adapt
immun
respons
develop
attenu
rv
vaccin
mucos
adjuv
mimic
immun
respons
virul
rv
may
improv
exist
vaccin
immunogen
protect
efficaci
rv
vaccin
formul
attenu
replic
viru
inactiv
viru
recombin
baculovirusexpress
viruslik
particl
vlp
administr
rout
adjuv
also
evalu
use
gnotobiot
pig
model
bohl
et
al
yuan
saif
gonzalez
et
al
inactiv
oral
intramuscular
rv
vaccin
fail
protect
virul
rv
challeng
despit
high
igg
antibodi
respons
induc
serum
system
lymphoid
tissu
serum
igg
antibodi
correl
protect
howev
recent
studi
show
inactiv
reassort
rv
strain
strain
formul
aluminum
phosphat
administ
system
gnotobiot
pig
result
induct
serum
igg
antibodi
titer
coincid
partial
protect
shed
diarrhea
suggest
adjuv
may
stimul
local
specif
gut
iga
antibodi
nonspecif
immun
respons
assess
studi
wang
et
al
rotaviru
subunit
vaccin
consist
doublelay
vlp
compos
rv
inner
capsid
protein
administ
oral
mutant
heatlabil
toxin
e
coli
mlt
iscom
adjuv
yuan
saif
induc
igg
asc
respons
system
lymphoid
tissu
low
iga
asc
respons
intestin
lymphoid
tissu
also
fail
mediat
protect
contrari
result
adult
mous
studi
yuan
saif
failur
oral
vaccin
suggest
protect
immun
rv
diarrhea
neonat
pig
requir
mainli
presenc
system
intestin
iga
antibodi
outer
capsid
rv
protein
induc
na
howev
adjuv
mlt
iscom
use
oral
booster
dose
pig
oral
prime
attenu
rv
protect
efficaci
increas
significantli
oral
attenu
rv
prime
boost
regimen
induc
highest
number
intestin
iga
asc
serum
intestin
iga
antibodi
titer
protect
rate
similar
higher
induc
three
oral
dose
attenu
rv
gonzalez
et
al
azevedo
et
al
interestingli
prime
two
dose
oral
follow
live
attenu
rv
ineffect
induc
iga
antibodi
protect
thu
use
replic
vaccin
prime
one
induct
site
galt
follow
boost
nonrepl
vaccin
second
mucos
induct
site
nasalassoci
lymphoid
tissu
nalt
effect
strategi
stimul
protect
mucos
immun
respons
appli
enter
viral
vaccin
furthermor
efficaci
primeboost
strategi
replicatingnonrepl
vaccin
examin
presenc
high
low
titer
passiv
antibodi
mimic
neonat
pig
receiv
matern
antibodi
nguyen
et
al
b
similar
primeboost
vaccin
studi
plasmid
dna
contain
use
booster
subsequ
oral
attenu
rv
vaccin
prime
regimen
show
high
protect
shed
poor
efficaci
rv
diarrhea
yuan
et
al
collect
find
suggest
mucos
booster
effect
enhanc
iga
antibodi
titer
rv
oral
prime
anim
studi
shown
immunogen
efficaci
mucos
vaccin
improv
use
appropri
strain
probiot
modul
mucos
system
immun
respons
interact
epitheli
cell
underli
intestin
immun
cell
fukushima
et
al
sanz
de
palma
certain
probiot
strain
report
enhanc
immun
respons
rv
vaccin
children
other
reduc
rv
diarrhea
sever
mechan
well
defin
fang
et
al
holscher
et
al
supplement
lactobacillu
acidophilu
attenu
rv
vaccin
pig
report
enhanc
intestin
cell
intestin
iga
igg
rv
asc
serum
iga
igg
rv
antibodi
titer
zhang
et
al
find
suggest
probiot
altern
cheap
safe
adjuv
enhanc
efficaci
oral
attenu
rv
vaccin
anim
potenti
human
colon
pig
two
differ
strain
lactic
acid
bacteria
lab
l
acidophilu
lactobacillu
reuteri
subsequ
virul
rv
infect
result
higher
balanc
cytokin
respons
higher
total
intestin
igasecret
cell
total
serum
igm
intestin
igm
igg
titer
although
number
iga
rv
asc
serum
intestin
rv
antibodi
titer
differ
compar
virul
rvonli
infect
pig
overal
differ
protect
rate
note
compar
virul
rvonli
inocul
pig
like
short
interv
day
lab
colon
virul
rv
challeng
zhang
et
al
azevedo
et
al
dual
colon
aforement
lab
strain
also
modul
innat
immun
compon
virul
rv
inocul
pig
follow
enhanc
frequenc
cell
intestin
distribut
enhanc
apc
apc
blood
reduc
apc
spleen
reduc
frequenc
cdc
spleen
collect
find
suggest
probiot
may
reduc
system
inflammatori
respons
induc
virul
rv
effect
tlr
express
apc
ileum
determin
zhang
et
al
wen
et
al
wen
et
al
probiot
may
modul
immun
respons
rv
enter
vaccin
may
also
directli
amelior
diarrheainfect
enhanc
gut
barrier
integr
maintain
intestin
permeabl
stimul
nonspecif
immun
respons
chang
gut
microbi
popul
aid
regul
prevent
apoptosi
madsen
et
al
yan
polk
preidi
et
al
use
tgev
model
evalu
activ
protect
diarrhea
pig
research
also
delin
compartment
common
mucos
immun
system
impact
mucos
vaccin
strategi
protect
vancott
et
al
vancott
et
al
natur
occurr
delet
mutant
tgev
exclus
respiratori
tropism
refer
porcin
respiratori
coronaviru
prcv
provid
uniqu
opportun
studi
asc
respons
protect
immun
two
antigen
relat
porcin
coronavirus
enter
tgev
versu
respiratori
prcv
tropism
oral
immun
pig
tgev
induc
high
number
iga
asc
intestin
provid
complet
protect
tgev
challeng
wherea
immun
pig
prcv
induc
mainli
system
respons
igg
asc
provid
partial
protect
tgev
challeng
thu
prcv
alon
fail
elicit
suffici
intestin
iga
asc
provid
full
protect
enter
pathogen
tgev
find
studi
rv
vaccin
studi
suggest
use
multipl
mucos
induct
site
primeboost
vaccin
regimen
may
effect
approach
overcom
compartment
common
mucos
immun
system
canin
parvoviru
cpv
infect
crypt
enterocyt
caus
hemorrhag
gastroenter
pup
saif
jackwood
cpv
like
dissemin
basolater
surfac
crypt
hematogen
rout
serum
na
deriv
matern
activ
produc
protect
diseas
pollock
carmichael
demonstr
pup
hemagglutin
inhibit
hi
serum
antibodi
titer
immun
oronas
cpv
type
challeng
cpv
highli
stabl
environ
pup
suscept
infect
soon
matern
antibodi
declin
hi
titer
matern
hi
antibodi
titer
low
sever
affect
efficaci
live
low
titer
cpv
vaccin
passag
cultur
gener
activ
immun
respons
carmichael
et
al
result
window
suscept
pup
other
shown
hi
titer
less
low
passag
high
titer
vaccin
pup
sever
affect
activ
antibodi
respons
burtonboy
et
al
hoar
et
al
suggest
increas
dose
reduc
attenu
viru
may
help
overcom
inhibitori
effect
matern
antibodi
studi
modifi
live
variant
strain
low
titer
shown
vaccin
given
either
parenter
passag
tissu
cultur
passag
elicit
almost
protect
pup
matern
antibodi
titer
even
protect
pup
antibodi
titer
higher
efficaci
vaccin
attribut
either
strong
inher
immunogen
new
vaccin
antigen
differ
among
pratelli
et
al
overal
past
four
decad
cpv
vaccin
develop
modifi
live
virus
proven
superior
inactiv
intramuscular
im
vaccin
appel
brief
variou
strategi
use
less
attenu
viru
low
serial
passag
high
titer
vaccin
multipl
dose
use
rout
immun
attempt
overcom
inhibitori
influenc
matern
antibodi
reduc
window
suscept
pup
recent
new
variant
emerg
highli
pathogen
caus
sever
diarrhea
dog
current
use
vaccin
strain
effect
protect
dog
challeng
viru
experiment
condit
spibey
et
al
although
efficaci
field
unknown
review
decaro
buonavoglia
antigen
differ
origin
variant
may
reduc
efficaci
current
cpv
vaccin
support
vitro
virusneutr
test
conduct
vaccin
anim
show
low
crossreact
heterolog
cpv
variant
caval
et
al
howev
may
repres
actual
crossprotect
clinic
case
need
make
current
vaccin
effect
presenc
matern
antibodi
also
updat
base
continu
epidemiolog
surveil
studi
dna
plasmid
express
jiang
et
al
repliconbas
cpv
dna
vaccin
express
dahiya
et
al
b
cell
epitop
peptid
fuse
ct
b
subunit
express
transgen
tobacco
chloroplast
molina
et
al
chimer
viru
particl
express
cpv
peptid
differ
primeboost
strategi
nichola
et
al
recombin
vlp
form
baculovirusexpress
casal
evalu
dog
rodent
without
matern
antibodi
demonstr
good
immunogen
andor
protect
efficaci
efficaci
test
pup
matern
antibodi
need
assess
commerci
potenti
oral
vaccin
induct
activ
immun
bacteri
diarrhea
commonli
use
livestock
although
e
coli
diarrhea
import
problem
neonat
postwean
calv
pig
major
fimbrial
adhesin
present
swine
enterotoxigen
e
coli
etec
major
target
e
coli
vaccin
fairbroth
et
al
whole
bacteria
vaccin
routin
administ
parenter
pregnant
cattl
sheep
swine
protect
suckl
neonat
etec
infect
moon
bunn
vaccin
practic
effect
fimbria
requir
adhesioncolon
bacteria
earli
pathogenesi
diseas
fatal
etec
infect
farm
anim
occur
neonat
period
etec
farm
anim
belong
small
famili
fimbrial
antigen
type
mother
seroposit
etec
booster
respons
elicit
recent
vaccin
studi
focus
administr
purifi
bacteri
subunit
transgen
express
adhesin
fimbria
plant
mucos
adjuv
verdonck
et
al
joensuu
et
al
shown
promis
result
overal
vaccin
strategi
use
parenter
vaccin
fieldexpos
seroposit
mother
induc
lactogen
immun
shown
effect
parenter
applic
rv
vaccin
rv
seroposit
mother
bohl
et
al
saif
jackwood
saif
fernandez
studi
live
oral
enter
vaccin
anim
clarifi
mechan
induct
protect
immun
enter
diseas
contribut
understand
common
mucos
immun
system
howev
commerci
live
oral
vaccin
often
shown
inadequ
inconsist
efficaci
field
condit
saif
jackwood
saif
fernandez
major
obstacl
improv
efficaci
oral
vaccin
includ
matern
antibodi
intestin
neonat
mainli
colostrum
milk
antibodi
interfer
live
vaccin
replic
qualit
quantit
limit
neonat
immun
system
although
neonat
immunocompet
inabl
attenu
vaccin
strain
adequ
infect
high
attenu
stimul
siga
antibodi
intestin
use
inappropri
unstabl
antigen
rout
subunit
vaccin
lack
oral
deliveri
vehicl
mucos
adjuv
subunit
vaccin
infect
pathogen
prior
vaccin
studi
neonat
pig
indic
protect
rate
rv
diarrhea
upon
challeng
correl
magnitud
iga
asc
memori
b
cell
respons
intestin
lymphoid
tissu
gonzalez
et
al
yuan
saif
studi
conduct
immunodefici
specif
gene
knockout
adult
mice
shown
neither
cell
antibodi
essenti
induct
protect
immun
rv
infect
usual
one
effector
b
cell
necessari
elimin
primari
rv
infect
mcneal
et
al
mcneal
et
al
pig
recent
studi
shown
produc
cell
play
role
protect
rv
diarrhea
infect
yuan
et
al
difficult
creat
genet
modifi
pig
similar
knockout
mice
assess
contribut
b
cell
cell
redund
natur
immun
respons
rv
mice
multipl
immunolog
possibl
nonimmunolog
pathway
resolv
rv
infect
franco
greenberg
ward
age
factor
host
differ
rv
pathogenesi
mice
pig
saif
et
al
ward
use
inbr
mous
strain
contribut
discrep
seen
adult
mous
neonat
pig
model
major
pathogen
enter
initi
infect
mucos
surfac
make
mucos
site
relev
target
vaccin
prevent
infect
develop
effect
mucos
vaccin
import
determin
correl
protect
enter
pathogen
gener
local
gut
infect
siga
antibodi
intestin
cell
play
import
role
improv
vaccin
induc
high
level
intestin
iga
antibodi
appropri
microbi
antigen
achiev
choos
proper
vaccin
formul
deliveri
method
vaccin
also
induc
heterotyp
protect
activ
immun
presenc
matern
antibodi
longlast
immunolog
memori
novel
vaccin
eg
vlp
transgen
plant
adjuv
eg
mlt
iscom
tlr
ligand
eg
cpg
mycobacteri
extract
retino
acid
probiot
cytokin
vaccin
deliveri
system
eg
recombin
plant
anim
virus
bacteri
vector
genet
engin
probiot
iscom
liposom
nanoparticl
explor
evalu
relev
anim
model
enhanc
efficaci
current
new
vaccin
recent
studi
shown
target
antigen
directli
apc
via
surfac
receptor
effect
way
tailor
immun
respons
optim
protect
explor
larg
anim
trumpfhel
et
al
passiv
transfer
matern
immun
provid
essenti
protect
newborn
although
neonat
immun
system
compet
mount
primari
immun
respons
pathogen
primari
respons
often
develop
quickli
enough
prevent
diseas
matern
immunolog
transfer
provid
critic
though
temporari
aid
surviv
neonat
enhanc
passiv
immun
vaccin
mother
success
diseas
prevent
strategi
domest
anim
vaccin
mother
develop
higher
level
specif
antibodi
colostrum
milk
increas
level
immun
offspr
glezen
saif
fernandez
passiv
immun
also
enhanc
oral
administr
immun
milk
heterolog
antibodi
prepar
eg
chicken
egg
yolk
igi
ikemori
et
al
kuroki
et
al
monoclon
antibodi
parenter
administr
hyperimmun
plasma
becu
et
al
recent
studi
use
monoclon
singlechain
antibodi
variabl
heavi
domain
vhh
nanoantibodi
llama
origin
open
new
possibl
provid
passiv
immun
human
anim
garaicoechea
et
al
immunoglobulin
isotyp
camelid
consist
heavi
chain
without
associ
light
chain
hamerscasterman
et
al
distinct
biochem
characterist
bind
qualiti
vhh
antibodi
overcom
key
limit
convent
antibodi
see
unfortun
passiv
antibodi
often
interfer
activ
immun
young
anim
bird
variou
vaccin
strategi
develop
minim
suppress
effect
matern
antibodi
improv
adjuv
antigendeliveri
system
need
facilit
effici
induct
activ
immun
presenc
matern
antibodi
section
address
past
current
futur
approach
enhanc
passiv
immun
veterinari
speci
transfer
system
passiv
immun
mother
offspr
occur
prenat
via
placenta
yolk
sac
postnas
via
ingest
colostrum
milk
depend
speci
main
ig
isotyp
transfer
mammalian
speci
igg
avian
speci
igi
function
equival
mammalian
igg
transfer
yolk
passiv
protect
develop
chick
kovacsnolan
mine
primat
rabbit
matern
igg
transfer
across
placenta
fetu
rodent
transplacent
transfer
occur
combin
prolong
day
postnat
transfer
mean
colostrum
milk
husband
dog
cat
transfer
igg
occur
combin
prenat
postnat
mechan
total
transfer
occur
birth
tizard
rumin
hors
pig
offspr
born
virtual
agammaglobulinem
transmiss
ig
occur
via
colostrum
limit
time
birth
tizard
transit
product
colostrum
milk
ig
longer
absorb
intestin
act
local
gastrointestin
tract
immunoglobulin
absorpt
neonat
larg
domest
speci
facilit
presenc
proteas
inhibitor
colostrum
effici
declin
rapidli
birth
maxim
absorpt
occur
first
h
cessat
absorpt
intact
macromolecul
term
gut
closur
occur
differ
age
differ
speci
calv
pig
closur
normal
occur
h
birth
absorpt
colostrum
ig
highli
effect
suppli
newborn
serum
ig
concentr
similar
dam
failur
passiv
transfer
fpt
common
problem
howev
newborn
calv
foal
besser
gay
tylermcgowan
et
al
fpt
may
occur
product
low
quantiti
colostrum
product
colostrum
low
concentr
matern
antibodi
ingest
low
quantiti
colostrum
ineffici
absorpt
quigley
drewri
colostrum
supplement
colostrum
replac
plasma
product
develop
commerci
address
problem
variabl
success
vaccin
dam
late
pregnanc
enhanc
antibodi
titer
colostrum
suckl
serum
offspr
saif
fernandez
benefit
vaccin
dam
enhanc
passiv
immun
lost
colostrum
low
qualiti
absorpt
colostr
ig
ineffici
halflif
ig
vari
consider
among
speci
domest
anim
ig
isotyp
neonat
receptor
fc
igg
fcrn
involv
homeostasi
serum
level
igg
gener
distinct
mechan
may
function
neonat
main
rout
clearanc
passiv
acquir
matern
calv
transfer
serum
intestin
besser
et
al
approxim
passiv
acquir
elimin
rout
titer
passiv
circul
antibodi
high
enough
transfer
antibodi
circul
intestin
lumen
mediat
shortterm
protect
rotaviru
diarrhea
besser
et
al
mechan
may
function
piglet
saif
wesley
et
al
ward
et
al
persist
titer
circul
matern
antibodi
gener
consid
design
vaccin
strategi
young
anim
suppress
effect
matern
antibodi
activ
immun
respons
induct
immun
memori
occur
absenc
detect
serum
antibodi
respons
boersema
et
al
et
al
presenc
passiv
antibodi
intestin
interfer
mucos
immun
respons
natur
infect
well
vaccin
et
al
nguyen
et
al
b
experi
colostrumdepriv
lamb
jone
et
al
calv
mosier
et
al
demonstr
abil
parenter
administ
immun
antisera
mediat
protect
follow
experiment
challeng
mannheimia
haemolytica
parenter
administr
hyperimmun
plasma
rais
rhodococcu
equi
shown
protect
pneumonia
young
foal
experiment
hoopermcgrevi
et
al
field
studi
becu
et
al
hyperimmun
plasma
avail
commerci
use
foal
prepartum
vaccin
beef
van
donkersgo
et
al
dairi
hodgin
shewen
cow
demonstr
increas
antibodi
titer
haemolytica
colostrum
serum
calv
vaccin
broiler
breeder
chicken
use
provid
passiv
protect
respiratorysepticem
diseas
caus
avian
pathogen
e
coli
kariyawasam
et
al
rodent
popular
model
studi
passiv
protect
milk
antibodi
howev
rat
mice
activ
transport
igg
gut
circul
first
week
life
thu
antibodi
ingest
milk
contribut
local
system
immun
rodent
contrast
strictli
local
effect
occur
human
domest
anim
pig
hors
dog
cat
igg
abund
ig
colostrum
iga
predomin
milk
parenter
vaccin
enhanc
serum
igg
antibodi
titer
contribut
igg
antibodi
colostrum
limit
effect
iga
antibodi
milk
milk
antibodi
provid
passiv
protect
neonat
intestin
tract
immun
exclus
prevent
attach
virus
bacteria
parasit
neutral
virus
enterotoxin
siga
antibodi
resist
cleavag
digest
enzym
higher
level
milk
effici
mediat
protect
gut
pig
monogastr
saif
jackwood
high
persist
level
passiv
igg
antibodi
also
protect
rumin
antibodi
rel
resist
proteolyt
enzym
brock
et
al
predomin
milk
function
similar
siga
numer
vaccin
market
vaccin
cow
sow
provid
lactogen
immun
rotaviru
coronaviru
e
coli
suckl
offspr
vaccin
efficaci
variabl
ideal
suckl
anim
becom
subclin
infect
enter
pathogen
receiv
adequ
passiv
antibodi
prevent
diseas
develop
activ
immun
prevent
subsequ
diarrhea
balanc
passiv
immun
diseas
disrupt
intens
anim
product
system
expos
anim
pathogen
confin
contamin
environ
earlier
wean
practic
reduc
intak
milk
antibodi
matern
enter
vaccin
commonli
use
two
popul
pregnant
anim
control
epidem
infect
use
seroneg
anim
induc
primari
immun
respons
control
endem
infect
rotaviru
e
coli
booster
vaccin
use
seroposit
fieldexpos
anim
stimul
anamnest
memori
respons
virul
tgev
given
pregnant
sow
stimul
high
level
iga
antibodi
milk
passiv
protect
saif
jackwood
oral
attenu
tgev
vaccin
replic
poorli
sow
induc
lower
iga
milk
antibodi
titer
low
variabl
efficaci
field
moxley
olson
parenter
kill
tgev
vaccin
induc
low
igg
milk
antibodi
titer
lowest
protect
rate
attempt
develop
matern
tgev
recombin
subunit
vaccin
base
surfac
tgev
spike
protein
induc
na
live
vector
vaccin
express
protein
also
limit
success
tgev
seroneg
swine
saif
wesley
howev
primeboost
strategi
im
administr
tgev
protein
follow
oralin
prime
attenu
tgev
shown
promis
mean
enhanc
iga
milk
antibodi
titer
park
et
al
booster
vaccin
strategi
requir
enhanc
lactogen
immun
endem
enter
pathogen
rotaviru
e
coli
antibodi
titer
milk
declin
dramat
lactat
breast
milk
iga
antibodi
increas
women
endem
expos
cholera
follow
parenter
boost
cholera
vaccin
svennerholm
et
al
pig
infect
rotaviru
iga
memori
b
cell
initi
resid
ileal
pp
subsequ
present
substanti
number
spleen
yuan
et
al
system
stimul
iga
memori
b
cell
parenter
booster
vaccin
yield
dimer
iga
antibodi
serum
transport
mucos
secret
via
polymer
ig
receptor
field
condit
antibodi
endem
intestin
pathogen
also
common
bovin
colostrum
milk
without
boost
effect
highli
immunogen
vaccin
antibodi
titer
often
low
protect
calv
besser
gay
saif
fernandez
thu
vaccin
market
prepartum
vaccin
cow
rotaviru
coronaviru
e
coli
enhanc
passiv
immun
calv
field
efficaci
vaccin
question
waltnertoew
et
al
vaccin
pregnant
dairi
cow
modifi
live
binari
ethyleneamin
inactiv
rotaviru
recombin
vlp
shown
increas
viru
na
titer
rotaviru
colostrum
milk
mediat
passiv
protect
calv
oral
rotaviru
challeng
saif
fernandez
kim
et
al
prepartum
vaccin
cow
sow
bacterin
prepar
enteropathogen
epec
e
coli
prevent
diarrhea
offspr
also
commonli
practic
modern
farm
practic
dairi
veal
calv
rare
fed
whole
milk
dam
day
thu
vaccin
efficaci
base
antibodi
absorb
colostrum
retain
temporarili
gut
rather
continu
suppli
immun
milk
piglet
contrast
continu
receiv
immun
milk
wean
week
age
import
continu
suppli
passiv
antibodi
protect
tgev
demonstr
saif
wesley
numer
commerci
ig
prepar
antibodi
activ
specif
enter
pathogen
market
product
intend
prevent
e
coli
enter
calv
includ
dri
bovin
colostrum
whey
hyperimmun
sera
rais
hors
mous
monoclon
antibodi
antigen
e
coli
product
administ
oral
first
h
life
prevent
adhes
epec
e
coli
oral
administ
bovin
colostr
whey
contain
rotaviru
antibodi
also
passiv
protect
piglet
rotaviru
schaller
et
al
immun
chicken
show
promis
effici
method
produc
polyclon
antibodi
passiv
protect
specif
antibodi
igi
isotyp
induc
vaccin
concentr
egg
yolk
lay
hen
produc
g
igi
per
year
yolk
antibodi
viru
na
provid
calv
partial
protect
diarrhea
caus
rotaviru
kuroki
et
al
vega
et
al
etec
e
coli
ikemori
et
al
recent
studi
supplement
milk
ration
neonat
calv
egg
yolk
contain
igi
antibodi
rotaviru
day
provid
protect
rotaviru
diarrhea
challeng
also
enhanc
mucos
asc
number
duodenum
vega
et
al
egg
yolk
lack
rotaviru
specif
igi
provid
clinic
protect
enhanc
asc
respons
suggest
presenc
immun
modul
egg
yolk
protect
effect
yolk
antibodi
depend
antibodi
titer
oral
prepar
marquardt
develop
better
mean
protect
yolk
antibodi
digest
process
improv
efficaci
econom
viabil
yolk
antibodi
clinic
applic
kovacsnolan
mine
mani
diseas
newborn
neonat
passiv
immun
practic
mean
provid
time
protect
unfortun
well
document
matern
antibodi
suppress
activ
immun
respons
follow
vaccin
effect
observ
live
nonrepl
vaccin
system
mucos
respons
siegrist
et
al
hodgin
et
al
et
al
nguyen
et
al
b
antibodi
respons
especi
affect
tlymphocyt
respons
may
suppress
siegrist
et
al
titer
matern
antibodi
maxim
speci
interest
first
week
life
declin
gradual
next
month
variabl
titer
among
individu
high
mani
vaccin
window
diseas
suscept
variabl
durat
occur
titer
matern
antibodi
low
mediat
protect
high
permit
effect
vaccin
number
strategi
use
cope
problem
veterinari
vaccin
cattl
sold
disclaim
anim
vaccin
month
age
receiv
booster
dose
vaccin
month
age
provid
littl
solac
mani
diseas
cattl
occur
first
week
month
life
common
strategi
vaccin
dog
cat
administ
seri
dose
vaccin
earli
age
time
individu
respons
continu
vaccin
age
virtual
respond
vaccin
strategi
econom
disadvantag
pet
owner
manufactur
produc
low
passag
high
viru
titer
vaccin
especi
use
situat
high
titer
matern
antibodi
high
pathogen
exposur
anticip
similar
strategi
longer
approv
world
health
organ
vaccin
children
develop
countri
measl
gellin
katz
preliminari
evid
suggest
incorpor
vaccin
antigen
highli
structur
iscom
applic
vaccin
enhanc
immun
respons
presenc
matern
antibodi
van
binnendijk
et
al
brockmeier
et
al
immunoglobulin
g
mammalian
speci
compos
two
heavi
chain
coval
link
disulfid
bond
two
light
chain
convent
heavi
chain
consist
one
variabl
domain
three
constant
domain
light
chain
compos
variabl
constant
domain
contrast
camelid
speci
produc
heavi
chain
immunoglobulin
lack
light
chain
first
constant
heavi
domain
hamerscasterman
et
al
antigenbind
site
unusu
heavi
chain
antibodi
form
singl
domain
design
vhh
camelid
vhh
easili
produc
recombin
protein
design
singl
domain
nanoantibodi
nanobodi
repres
smallest
molecul
natur
capabl
bind
specif
antigen
region
nanobodi
capac
form
long
loop
extend
caviti
antigen
eg
activ
site
crevic
enzym
advantag
featur
nanobodi
includ
high
solubl
thermal
stabil
resist
pasteur
refold
capac
optim
tissu
penetr
vivo
review
vanlandschoot
et
al
nanobodi
demonstr
efficaci
agent
passiv
immun
infecti
diseas
vhh
specif
rotaviru
inner
capsid
protein
abl
broadli
neutral
rotavirus
independ
serotyp
mous
experi
provid
passiv
protect
challeng
human
rotaviru
pant
et
al
garaicoechea
et
al
nanobodi
viral
diseas
veterinari
impact
develop
footandmouth
diseas
influenza
rabi
vanlandschoot
et
al
repres
promis
nextgener
biolog
platform
passiv
immun
matern
vaccin
enhanc
passiv
immun
alreadi
wide
use
veterinari
medicin
vaccin
especi
vaccin
enter
virus
limit
efficaci
new
approach
enhanc
immunogen
promis
await
commerci
develop
clearer
understand
protect
mechan
immun
modul
mediat
passiv
antibodi
would
contribut
effect
intervent
urgent
need
adjuv
deliveri
system
capabl
reliabl
induc
activ
immun
neonat
despit
presenc
matern
antibodi
abil
provid
continu
immun
protect
birth
combin
passiv
immun
activ
immun
would
major
impact
neonat
morbid
mortal
rapid
expans
commerci
fish
farm
aquacultur
mani
countri
recent
decad
accompani
urgent
need
develop
vaccin
prevent
infecti
fish
diseas
previous
unknown
obscur
ad
difficulti
involv
identifi
pathogen
respons
challeng
deliv
vaccin
effici
minim
stress
larg
number
fish
commerci
vaccin
fish
administ
intraperiton
im
inject
mucos
vaccin
also
wide
use
review
brudeseth
et
al
fish
routin
vaccin
immers
tank
dilut
bacterin
modifi
live
bacteria
virus
exposur
time
rang
min
depend
vaccin
age
fish
unclear
whether
main
rout
antigen
uptak
oral
via
mucos
surfac
gill
sever
commerci
vaccin
avail
consist
recombin
viral
protein
mix
feed
evensen
leong
day
feed
recommend
manufactur
research
mucos
veterinari
vaccin
contribut
new
concept
field
mucos
immun
investig
pathogenhost
interact
outbr
anim
illustr
complex
interact
earli
studi
enter
coronaviru
infect
swine
tgev
led
concept
gutmammari
gland
siga
immunolog
axi
provid
part
basic
tenet
common
mucos
immun
system
later
studi
tgev
delet
mutant
tgev
respiratori
tropism
prcv
reveal
function
compartment
within
common
mucos
immun
system
wherebi
inocul
pig
prcv
fail
elicit
suffici
intestin
iga
antibodi
fulli
protect
enter
pathogen
tgev
vancott
et
al
vancott
et
al
subsequ
studi
explor
new
primeboost
mucos
immun
strategi
elicit
intestin
immun
rotaviru
pig
saif
yuan
saif
gonzalez
et
al
studi
oral
prime
attenu
viru
led
success
booster
respons
use
nonrepl
vlp
vaccin
combin
mucos
adjuv
iscom
mlt
thu
use
replic
vaccin
prime
lymphocyt
major
mucos
induct
site
galt
follow
boost
nonrepl
vaccin
second
induct
site
nalt
effect
stimul
intestin
iga
antibodi
induc
activ
protect
rotaviru
diarrhea
although
progress
develop
safe
effect
nonrepl
vaccin
boost
mucos
immun
respons
saif
fernandez
dilemma
remain
develop
effect
vaccin
prime
mucos
immun
mucos
adjuv
mlt
iscom
cpg
cytokin
new
deliveri
system
replic
vector
microparticl
shown
promis
anim
studi
review
chapter
howev
econom
product
final
evalu
field
condit
includ
presenc
matern
antibodi
relev
need
consider
research
effort
devot
develop
vaccin
respiratori
diseas
domest
anim
instanc
attenu
organ
deliv
mucos
rout
demonstr
improv
efficaci
nonrepl
antigen
given
system
rout
mani
respiratori
diseas
howev
progress
develop
mucos
vaccin
await
advanc
understand
diseas
pathogenesi
identif
protect
antigen
contrast
studi
ascend
infect
reproduct
tract
cattl
demonstr
efficaci
system
vaccin
clear
establish
infect
highlight
possibl
therapeut
vaccin
final
import
realiz
consider
speci
differ
mucos
immun
exampl
primari
ig
mammari
secret
rumin
activ
transport
mammari
gland
serum
provid
effect
passiv
immun
nurs
offspr
enter
pathogen
thu
parenter
immun
dam
stimul
passiv
immun
rumin
enter
pathogen
contrast
monogastr
iga
predomin
milk
iga
lymphoblast
traffic
mammari
gland
origin
intestin
therefor
oral
vaccin
monogastr
may
provid
effect
vaccin
strategi
induc
iga
antibodi
milk
saif
fernandez
appli
aforement
vaccin
concept
new
effect
mucos
adjuv
deliveri
system
bioengin
vector
express
appropri
microbi
antigen
like
new
gener
veterinari
vaccin
emerg
better
cope
exist
emerg
mucos
pathogen
